Displaying 801 - 820 of 1017 results

Frequently Asked Questions for PAR-24-289 (R01) and PAR-25-230 (R21): Ancillary Studies to Ongoing Clinical Projects (Clinical Trial Not Allowed)

https://www.niams.nih.gov/grants-funding/funding-opportunities/supported-scientific-areas/PAR-ancillary-studies-faqs

Applicants with additional questions are highly encouraged to contact their Program Director . These FAQs apply to the following funding opportunities: Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) (PAR-24-289) Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) (PAR-25-230)

The Stephen I. Katz Early Stage Investigator Research Grant Program

https://www.niams.nih.gov/grants-funding/applying-grant/grant-review-process/stephen-i-katz-early-stage-investigator-research

Dr. Stephen I. Katz directed the National Institute of Arthritis and Musculoskeletal and Skin Diseases from August 1995 until his death in December 2018. He is remembered as an outstanding scientist, administrator, and civil servant who was committed to excellence, transparency, integrity, and public trust. But perhaps most noteworthy were

New NIH Research Grants Honor Legacy of Former NIAMS Director Stephen I. Katz, M.D., Ph.D.

https://www.niams.nih.gov/about/about-the-director/letter/new-nih-research-grants-honor-legacy-of-former-niams-director

We at NIAMS are excited as we look forward to the arrival of Lindsey Criswell as the new Director but our thoughts also turn back to memories of our previous Director, Steve Katz. He was a unique voice who guided the NIAMS as director for more than two decades and who spent his career mentoring the next generations of researchers. With this in mind, I am pleased to share news of new awards that give the NIH a unique way to encourage the scientists of tomorrow.

Frequently Asked Questions for Investigators Conducting NIAMS-Funded Clinical Research Studies

https://www.niams.nih.gov/grants-funding/funding-opportunities/supported-scientific-areas/frequently-asked-questions-investigators-conducting-niams-funded-clinical-research-studies

TABLE OF CONTENTS TERMINOLOGIES AND DEFINITIONS GENERAL DATA AND SAFETY MONITORING AND OVERSIGHT STUDY DOCUMENTS NIAMS CLINICAL FUNDING OPPORTUNITIES, REVIEW AND AWARD ANCILLARY STUDIES HUMAN SUBJECTS AND CLINICAL TRIALS INFORMATION FORM CLINICALTRIALS.GOV TRAINING REQUIREMENTS FOR CLINICAL TRIALS

Data and Safety Monitoring (DSM) Guidelines for Internal Safety Monitoring

https://www.niams.nih.gov/grants-funding/conducting-clinical-trials/clinical-trial-policies-guidelines-and-templates/data-0

Learn NIAMS guidance and guidelines for studies that use internally-appointed monitoring for the oversight of NIAMS-funded clinical research. TABLE OF CONTENTS 1.0 Internally-appointed Monitoring 1.1 Roles and Responsibilities of the PI 1.2 Responsibilities of Internally-appointed Monitoring Body 1.2.a Internal Safety Monitoring Process 1.2.b Internal Review of Data and Safety Reports

Scientific Director

https://www.niams.nih.gov/about/niams-leadership/scientific-director-of-intramural-research

The Office of the Scientific Director (OSD) is responsible for oversight, review, and administration of the Intramural Research Program (IRP) at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The OSD has several key functions, including planning, coordinating, and directing the basic and clinical scientific research programs conducted within the IRP.

Typically materials from NIAMS that are more than 5 years old will be archived.

Back to Top